Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elutia Inc. filings document the regulatory record for a medical technology company developing and commercializing drug-eluting biomatrix products. Form 8-K reports cover financial results, preliminary operating updates, Nasdaq listing notices and compliance events, and material compensation actions tied to the company's Class A common stock.
Proxy materials disclose board matters, executive compensation, equity-award information, shareholder voting items, and governance practices. The filing record also includes disclosures on inducement award plans, stock-based compensation capacity, registered securities on the Nasdaq Capital Market, and emerging growth company status.
Elutia Inc. reported first-quarter 2026 net sales of $3.1 million, up modestly from $3.0 million a year earlier, with gross profit improving to $1.8 million from $1.4 million as cost of goods sold declined.
The company posted a net loss of $7.5 million compared with a $3.9 million loss in 2025, mainly reflecting a $1.7 million loss on revaluation of warrant liability and higher research and development spending as it advances NXT-41 and NXT-41x. Cash and cash equivalents were $28.5 million, and operating cash outflow was $7.8 million. Results also reflect discontinued operations gains tied to prior divestitures and sizable contingent liabilities and insurance receivables related to FiberCel and viable bone matrix litigation.
Elutia Inc. reported first quarter 2026 results, combining higher revenue with a wider loss as it invests in its drug-eluting biomatrix platform. Net sales from continuing operations were $3.1 million, slightly above the prior-year period, while net loss widened to $7.5 million from $3.9 million. GAAP gross margin improved to 57.9%, and adjusted gross margin rose to 66.5%, reflecting early benefits from automated manufacturing.
The company highlighted progress on its breast reconstruction pipeline. FDA review of the 510(k) for NXT-41 remains on track for anticipated clearance in the fourth quarter of 2026, with NXT-41x clearance anticipated in the first half of 2027. Elutia is advancing strategic processes for a potential SimpliDerm divestiture and evaluating acquisition interest in its Cardiovascular product line. Cash and escrowed funds totaled $36.5 million as of March 31, 2026, including $8.0 million in escrow related to a prior divestiture that is expected to be released in the fourth quarter of 2026.
Elutia Inc. reported first quarter 2026 results, combining higher revenue with a wider loss as it invests in its drug-eluting biomatrix platform. Net sales from continuing operations were $3.1 million, slightly above the prior-year period, while net loss widened to $7.5 million from $3.9 million. GAAP gross margin improved to 57.9%, and adjusted gross margin rose to 66.5%, reflecting early benefits from automated manufacturing.
The company highlighted progress on its breast reconstruction pipeline. FDA review of the 510(k) for NXT-41 remains on track for anticipated clearance in the fourth quarter of 2026, with NXT-41x clearance anticipated in the first half of 2027. Elutia is advancing strategic processes for a potential SimpliDerm divestiture and evaluating acquisition interest in its Cardiovascular product line. Cash and escrowed funds totaled $36.5 million as of March 31, 2026, including $8.0 million in escrow related to a prior divestiture that is expected to be released in the fourth quarter of 2026.
Elutia Inc. is asking stockholders to approve several items at its June 11, 2026 annual meeting, including director elections, auditor ratification, an equity plan amendment, and advisory votes on executive pay and pay-vote frequency.
The company proposes adding 3,000,000 shares to its 2020 Incentive Award Plan, extending its annual share “evergreen” increase of up to 4% of outstanding common stock through 2036, and moving the plan’s termination date to the tenth anniversary of April 22, 2026. As of April 17, 2026, 44,208,236 Class A shares were outstanding and 810,198 shares remained available under the plan. Elutia also seeks to re-elect two Class III directors, hold future say-on-pay votes annually, and ratify PricewaterhouseCoopers LLP as auditor for 2026.
ELUTIA INC. director Guido J. Neels exercised restricted stock units that vested into 6,250 shares of Class A Common Stock at a price of $0.00 per share. These shares came from a grant of 25,000 restricted stock units that vests in four equal installments. Following this vesting and conversion, Neels directly owns 125,000 shares of Class A Common Stock.
Elutia Inc. is reshaping its business around drug‑eluting biomatrix products for reconstructive surgery after selling noncore segments. In October 2025 it sold substantially all assets of its cardiac implantable electronic device business to Boston Scientific and an affiliate for up to $88.0 million in cash, recognizing a $76.1 million gain. Earlier, it divested its Orthobiologics segment for $14.6 million plus up to $20.0 million of potential earn‑outs and has already recorded gains of $6.2 million. The company is now centered on SimpliDerm and cardiovascular patches while developing next‑generation programs NXT‑41 and NXT‑41x, which combine biologic scaffolds with local antibiotic delivery and are targeted for FDA clearance in the second half of 2026 and by mid‑2027, respectively.
Elutia remains loss‑making, with losses from continuing operations of $26.9 million in 2025 and $30.7 million in 2024, and depends on growing its Women’s Health and Cardiovascular businesses and successfully launching NXT‑41x. It also faces significant product‑liability exposure from recalls of FiberCel and viable bone matrix products, with an estimated contingent liability of $11.2 million, including $6.8 million for FiberCel where insurance coverage is exhausted. As of March 4, 2026, Elutia had 42,784,848 Class A shares outstanding and 26 employees, and is emphasizing a lean, integrated R&D, manufacturing and commercialization model to support its focused growth strategy.
Elutia Inc.’s Chief Scientific Officer, Michelle LeRoux Williams, increased her direct equity stake through restricted stock unit vesting. On March 10, 2026, 12,500 restricted stock units converted into an equal number of Class A Common shares, reflecting previously granted equity compensation.
To cover tax withholding on this vesting, 4,613 shares of Class A Common Stock were withheld by the company at a price of $1.09 per share, leaving a net 7,887 newly held shares. Following these routine compensation-related transactions, she directly owns 109,821 shares of Class A Common Stock and 37,500 restricted stock units, each representing a contingent right to receive one share.
Elutia Inc. President and CEO C. Randal Mills reported compensation-related stock activity. On 2026-03-10, restricted stock units vested, resulting in the acquisition of 27,084 shares of Class A Common Stock, with each unit representing one share. The issuer withheld 11,100 shares at $1.09 per share to cover tax obligations associated with the vesting. Following these transactions, Mills directly holds 409,406 shares of Class A Common Stock, indicating a routine equity award vesting and related tax withholding rather than an open-market trade.
Elutia Inc.’s chief financial officer Matthew Ferguson reported routine equity compensation activity. On March 10, 2026, 12,500 restricted stock units vested and were exercised into 12,500 shares of Class A Common Stock. To cover tax obligations on this vesting, 5,123 shares were withheld by the company at a price of $1.09 per share, leaving a net increase of 7,377 shares. After these transactions, Ferguson directly owns 472,067 shares of Class A Common Stock. The vested RSUs are part of a 150,000-unit grant awarded on January 31, 2024, which vests in scheduled installments through December 10, 2026.
Elutia Inc. reported fourth-quarter and full-year 2025 results and highlighted a major strategic shift. Net sales from continuing operations were $3.3M in Q4 2025, up from $2.8M, but full-year 2025 sales declined to $12.3M from $14.5M.
Loss from continuing operations narrowed sharply to $15.9M in 2025 from $45.3M in 2024 as operating expenses fell. Thanks largely to a $88M BioEnvelope divestiture, income from discontinued operations was $69.3M, driving full-year net income of $53.4M versus a $53.9M loss in 2024.
Year-end cash and escrowed proceeds totaled $44.4M, with long-term debt eliminated and stockholders’ equity improving from a deficit of $(46.3M) to positive $27.7M. Elutia submitted its base biologic matrix NXT-41 to the FDA and expects NXT-41 clearance in the second half of 2026 and full NXT-41x clearance in the first half of 2027.